DEF 14A: Bausch + Lomb Sets Date for Virtual Annual Shareholder Meeting, Outlines Proposals

Bausch + Lomb Corporation will hold its 2024 Annual Meeting of Shareholders virtually on May 29, 2024, to vote on director elections, executive compensation, an incentive plan amendment, and auditor appointment.

Summary

• Bausch + Lomb Corporation will conduct its 2024 Annual Meeting of Shareholders virtually on May 29, 2024.
• Shareholders will vote on electing ten directors, approving executive compensation, amending the 2022 Omnibus Incentive Plan to increase common shares authorized for issuance by 14,000,000, and appointing PricewaterhouseCoopers LLP as the company's auditor.
• The Board recommends voting FOR all director nominees, the advisory vote on executive compensation, the incentive plan amendment, and the auditor appointment.
• The meeting will be held online at www.virtualshareholdermeeting.com/BLCO2024 at 10:00 a.m. Eastern Daylight Time.
• The record date for the meeting is April 23, 2024.
• To be valid, votes must be received by Broadridge Financial Solutions, Inc. by 10:00 a.m. (EDT) on May 28, 2024.
• The board has set diversity targets for board composition, aiming for at least 30% representation from women or diverse communities.
• In 2023, the Board achieved 40% diversity, including gender and minority representation.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook, highlighting revenue growth and strategic initiatives. The tone is optimistic and forward-looking, suggesting confidence in the company's future performance.

Positives

• The Board recommends voting FOR all director nominees, the advisory vote on executive compensation, the incentive plan amendment, and the auditor appointment.
• The board has set diversity targets for board composition, aiming for at least 30% representation from women or diverse communities.
• In 2023, the Board achieved 40% diversity, including gender and minority representation.

Risks

• Failure to approve the amendment to the Omnibus Incentive Plan could put the company at a competitive disadvantage in attracting and retaining talent.
• If the company is unable to maintain its current equity grant practices, it may be compelled to replace equity incentive awards with cash awards, which may not align the interests of executives and employees with those of shareholders as effectively as equity incentive awards.

Future Outlook

The company anticipates 2024 will be one of its most active launch years in company history, expecting continued growth.

Management Comments

• Chairman and CEO Brenton L. Saunders expressed excitement about the future and highlighted progress on the Roadmap to Accelerate Growth, reflected in the company's 2023 performance.
• Saunders emphasized the importance of the global workforce's efforts in fundamentally changing how the company operates.

Industry Context

The document does not explicitly detail how this announcement relates to broader industry trends or competitors, but it emphasizes growth and innovation, which are key themes in the healthcare and vision care industries.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• However, it mentions revenue growth and strategic initiatives, which are common metrics used to evaluate performance in the pharmaceutical and healthcare sectors.
• Without specific benchmarks, it's difficult to assess how Bausch + Lomb's performance stacks up against industry leaders like Johnson & Johnson, Novartis (mentioned in relation to the XIIDRA acquisition), or Alcon (a direct competitor).

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The proposals directly impact shareholders through potential changes in company governance, executive compensation, and equity dilution.
• Employees: The incentive plan amendment affects employees' compensation and motivation.
• Customers: The company's strategic initiatives and product development impact the availability and quality of eye health solutions for customers.

Next Steps

• Shareholders are encouraged to vote as soon as possible.
• Shareholders are encouraged to attend Bausch + Lombs Annual Meeting of Shareholders on Wednesday, May 29, 2024, at 10:00 a.m. (Eastern Daylight Time).

Key Dates

Keywords

Annual Meeting, Shareholders, Proxy Statement, Board of Directors, Executive Compensation, Director Election, Omnibus Incentive Plan, Auditor Appointment, Corporate Governance, Bausch + Lomb